Importantly, in the first of these two studies, therapeutic blockade of the FasL pathway offered protection against auto-aggressive CD8+ T cells, uncovering the potential to limit liver damage in chronic liver diseases such as NASH (and therefore preventing the development of HCC), without compromising the efficacy of antigen specific immunity [116]. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatohepatitis.